title: [Clinical features of patients with malignant peritoneal mesothelioma initially presenting as a local inflammation].
authors.forename: Hui
authors.initials: H
authors.lastname: Song
authors.affiliation: Email: xhkzgq@sina.com.
authors.forename: Guoqi
authors.initials: G
authors.lastname: Zheng
authors.forename: Sichen
authors.initials: S
authors.lastname: Wei
authors.forename: Yuxin
authors.initials: Y
authors.lastname: Yang
authors.forename: Xinliang
authors.initials: X
authors.lastname: Wei
mesh_terms: D000368:Aged; D000971:Antineoplastic Combined Chemotherapy Protocols / Q000627:therapeutic use; D064032:Calbindin 2 / Q000378:metabolism; D002764:Cholecystitis / Q000473:pathology; D002945:Cisplatin / Q000008:administration & dosage; D003556:Cystitis / Q000473:pathology; D003937:Diagnosis, Differential; D005260:Female; D005971:Glutamates / Q000008:administration & dosage; D006147:Guanine / Q000008:administration & dosage / Q000031:analogs & derivatives; D006801:Humans; D007249:Inflammation / Q000473:pathology*; D007633:Keratins / Q000378:metabolism; D008175:Lung Neoplasms / Q000188:drug therapy / Q000378:metabolism / Q000473:pathology* / Q000601:surgery; D008297:Male; D008654:Mesothelioma / Q000188:drug therapy / Q000378:metabolism / Q000473:pathology* / Q000601:surgery; D000086002:Mesothelioma, Malignant; D008875:Middle Aged; D000068437:Pemetrexed; D010534:Peritoneal Neoplasms / Q000188:drug therapy / Q000378:metabolism / Q000473:pathology* / Q000601:surgery; D015996:Survival Rate; D014746:Vimentin / Q000378:metabolism
chemical_list: D064032:Calbindin 2; D005971:Glutamates; D014746:Vimentin; D000068437:Pemetrexed; D006147:Guanine; D007633:Keratins; D002945:Cisplatin